Cas no for 107868-30-4,Exemestane ACID Cas number search msds database,online free cas number chemistry search engine,cas number sigma aldrich

Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

Home > CAS No. Inquiry > 107868-30-4

107868-30-4

[CAS Name] Exemestane

[Formula] C20H24O2

Search Products Post Sourcing Request

Basica Info

[CAS Name]Exemestane
[Alias]Exemestan; 6-Methylenandrosta-1,4-diene-3,17-dione; 10,13-Dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-; 6-methylideneandrosta-1,4-diene-3,17-dione; (8ξ,9ξ,14ξ)-6-methylideneandrosta-1,4-diene-3,17-dione
[Number]107868-30-4
[EINECS]
[Formula]C20H24O2
[Molecular weight]296.4034

[Melting point]155.13℃
[Boiling point]453.7°C at 760 mmHg
[Density]2.02E-08mmHg at 25°C
[Flash point]169°C

107868-30-4 Suppliers

Company

Main Products

JIANGSU GRAND XIANLE PHARMACEUTICAL CO.,LTD.

Exemestane

Send Inquiry

Hanways Chempharm Co.,Limited

Brief Description

Product name	Exemestane
Synonyms	Exemestan; 6-Methylenandrosta-1,4-diene-3,17-dione; 10,13-Dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-; 6-methylideneandrosta-1,4-diene-3,17-dione; (8ξ,9ξ,14ξ)-6-methylideneandrosta-1,4-diene-3,17-dione; Exemestane(Aromasin); Exemestone
MOQ	25KG
CAS No.	107868-30-4
Appearance	An almost white powder
Molecular Formula	C20H24O2
Molecular Weight	296.4034
Assay	99%
Application	Pharma grade or research purpose
Packing	As per your request
Storage	Preserve in tight, light-resistant containers in a cool place
Remarks	NA
Custom synthesis	Available
Supply Ability	10000kg/month

Medical use

Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy. US FDA approval was in October 2005.

Exemestane is also indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Send Inquiry

Sinoway Industrial Co.Ltd.

Testing

Specification

Results

Appearance

Identification

Residue on Ignition

Heavy Metals

Water

Specific Optical Rotation

Impurity

Spirooxiran 1

Spirooxiran 2

Exemestane related(Compound C)

Exemestane related(Compound A)

Any unspecified impurity

Total impurity

Assay(HPLC)

Micron

White crystalline powder

RT (HPLC)

0.1% Max

10PPM Max

0.5% Max

+290° to +300°

0.15% Max

0.1% Max

0.5% Max

98% to 10.2%

100% Less than 20μm

Conform

0.04%

Conform

0.03%

+290.86°

Not Detected

0.05%

0.25%

100.02%

Conform

Conclusion: Up to Standard for USP Pending Monograph

Send Inquiry

Previous page 1 2 3 4 5 6 Next page

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us: About PharmaSources; Terms of Service; Privacy Policy; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go

PharmaSources Customer Service